Roche discontinues Genmab cancer drug
This article was originally published in Scrip
Executive Summary
Roche has discontinued development of the insulin-like growth factor-1 receptor (IGF-1R) inhibitor, RG1507, which was the most advanced product it was developing in collaboration with Genmab for various cancers.
You may also be interested in...
Horizon's Poor Primary Care Performance Overshadows River Vision Buy
Horizon's deal to buy River Vision to bolster its orphan product pipeline is cast into the shade by a disappointing first quarter performance for its primary care business.
2011 Scrip 100: A new look at cancer chemoprevention
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's Xeplion recommended for EU approval for schizophrenia
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.